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Overview: For more than three decades, alkylating agents
have been the most widely used class of chemotherapeutic
agents for the treatment of glial brain tumors. Today, con-
comitant and adjuvant temozolomide is the standard of care
for newly diagnosed glioblastoma. Temozolomide alone or in
combination with radiotherapy is being explored in ongoing
trials in newly diagnosed patients with low-grade and ana-
plastic glioma. Rechallenge with alternative dosing schedules
of temozolomide is a valid treatment option in recurrent,
temozolomide-pretreated patients with glioblastoma, and ni-
trosourea compounds are alternative treatment options in this
setting, in addition to novel, mostly antiangiogenic agents,
notably bevacizumab. Moreover, nitrosoureas have become
the gold standard comparator arm for the evaluation of novel
treatments in recurrent glioblastoma.
UNTIL THE past decade the use of chemotherapy forlow- and high-grade gliomas was mostly restricted to
salvage therapy following initial surgery and radiotherapy.
Clinical trials testing the role of adjuvant chemotherapy in
grade 3 and 4 gliomas showed minimal benefit with agents
such as the nitrosoureas and, perhaps surprisingly, even the
use of both neoadjuvant and adjuvant procarbazine, lomus-
tine (CCNU), and vincristine (PCV) chemotherapy failed to
show improved overall survival in the most chemosensitive
subtypes of glioma.1,2
In 2005, a pivotal European Organisation for the Research
and Treatment of Cancer (EORTC)/National Cancer Insti-
tute of Canada Clinical Trials Group (NCIC-CTG), trial
tested the incorporation of temozolomide concurrent with
radiotherapy followed by six maintenance cycles of adjuvant
chemotherapy for newly diagnosed glioblastoma.3 The study
found improved survival with benefit extending for several
years and set both a new standard of care and a new clinical
trials platform for the optimization of temozolomide/radio-
therapy in glioblastoma. In a subset analysis of patients
from this study, the clinical benefit was found to be mainly
restricted to patients harboring promoter methylation of
the DNA repair gene O6-methylguanine-DNA methyltrans-
ferase (MGMT), a key mechanism of MGMT gene silencing
that predicts a favorable outcome to combined-modality
therapy.4 The MGMT biomarker is currently used as an
important stratification variable in new clinical trials, such
as Radiation Therapy Oncology Group (RTOG) 0525, or even
to select patients for clinical trials, such as the CENTRIC
study, which compares radiotherapy plus temozolomide
with or without concomitant cilengitide, an integrin inhibi-
tor with promising activity and an excellent safety profile. At
present, the MGMT biomarker is not sufficiently character-
ized to be used to select patients for alkylator chemotherapy;
however, several ongoing prospective studies will soon be
completed and will clarify the role of MGMT as a predictive
versus prognostic biomarker and the role of routine testing
in clinical practice.5
Ongoing clinical trials now incorporate 60 Gy external
beam radiotherapy with concomitant temozolomide (75
mg/m2 orally, daily, for 6 weeks, including weekends) and
are exploring the additive value of additional cytotoxic,
cytostatic, and targeted therapies. The most ambitious of
these trials include the cilengitide program for patients with
MGMT-methylated tumors (phase III); schedule-intensified
cilengitide for MGMT-unmethylated tumors (phase II); the
addition of bevacizumab to standard upfront and adjuvant
therapy (AvaGlio trial); and RTOG 0825 (phase III). Other
studies seek to clarify the optimal duration and schedule of
adjuvant chemotherapy. RTOG 0525 is expected to have
early results available by the 2011 ASCO Annual Meeting
and may clarify the optimal schedule for adjuvant temozo-
lomide use (conventional 150–200 mg/m2 5-day therapy vs.
75 mg/m2 21-day therapy in an extended regimen) and may
also provide a wealth of prospective information on MGMT
and other important biomarkers and genetic profiles in
newly diagnosed glioblastoma.
For patients with anaplastic gliomas the addition of cyto-
toxic chemotherapy with agents such as temozolomide to
initial therapy is controversial. One can argue that if the
radiotherapy/temozolomide approach is beneficial in the
least chemosensitive type of glioma (glioblastoma), then it
should also be beneficial for grade 3 gliomas such as ana-
plastic astrocytoma and, especially, anaplastic oligodendro-
glioma harboring loss of heterozygosity of 1p and 19q.
Unfortunately, there is currently no level 1 evidence on
which to base such a treatment recommendation. Further-
more, for patients with survival times that can exceed a
decade, the long-term toxicities of currently available ther-
apies are poorly understood, and chemotherapy alone has
been identified as a promising alternative option for many
patients with anaplastic gliomas.6
Two recently developed clinical trials conducted through
international collaboration will help to answer some of these
questions for anaplastic gliomas. EORTC 26053 (NCIC-
CTG CEC.1, RTOG 0834) is a phase III randomized trial
of radiotherapy with or without concomitant temozolomide,
and with or without adjuvant temozolomide, in patients
with newly diagnosed anaplastic gliomas without 1p or 19q
deletions. This study should help to dissect the benefit of the
concomitant portion of temozolomide therapy from the ad-
juvant portion, compared with both together versus none at
all. In comparison, for the same histologic tumors (anaplas-
tic glioma) but with codeletion of 1p and 19q, a companion
phase III randomized trial consists of three arms: 1) stan-
dard radiotherapy alone; 2) standard radiotherapy with
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concomitant and adjuvant temozolomide; and 3) temozolo-
mide chemotherapy alone in the conventional 5-day sched-
ule (NCCTG-N0557, EORTC 26081–22086). Both of these
collaborative studies include robust molecular substudies.
The role of chemotherapy in low-grade gliomas remains
controversial. Although it is clear that some patients with
low-grade gliomas respond to chemotherapy, the optimal
timing, drug, and schedule of administration is unclear,
especially for newly diagnosed patients. Buckner and col-
leagues reported a phase II trial of upfront PCV chemo-
therapy followed by radiotherapy at completion or during
progression on chemotherapy and noted tumor regression in
52% (13 of 25 patients).7 In RTOG 9802, 251 patients with
lograde gliomas were randomly assigned to radiation ther-
apy alone versus radiation followed by six cycles of PCV.8 An
advantage in both progression-free and overall survival
favored the PCV arm; however, PCV resulted in significant
toxicity in some patients. Because of the widespread use of
temozolomide, there have been several trials exploring the
role of upfront temozolomide in patients with low-grade
glioma. Quinn and colleagues offered temozolomide at 200
mg/m2 in the conventional 5-day cycle to treatment-naive
patients with progressive low-grade glioma and saw an
objective response rate of 61% with a median progression-
free survival of 22 months.9 Others have explored the use of
protracted temozolomide (75 mg/m2/day for 21 days), finding
prolonged overall survival in patients with MGMT promoter
methylation.10,26 These studies demonstrate biologic activ-
ity of alkylator-based treatment of low-grade gliomas, but
add little to our understanding of the optimal type and
timing of treatment for these patients.
Future development of temozolomide and other nonradio-
therapy strategies for patients with low-grade glioma will
be enhanced by the development of improved response
assessment guidelines (an ongoing project of the Response
Assessment in Neuro-Oncology group) and discovery and
validation of current (MGMT, 1p/19q codeletion, isocitrate
dehydrogenase 1/2) and future biomarkers. Two ongoing
phase III trials are designed explore these questions. In
EORTC 22033 to 26033, NCIC-CTG CE.5, patients with
symptomatic or progressive low-grade glioma are stratified
according to 1p/19q codeletion and randomly assigned to
either 50.4 Gy radiotherapy alone versus temozolomide
alone (75 mg/m2/day for 21 days). In a complementary trial
administered by the Eastern Cooperative Oncology Group,
as many as 540 patients with known 19/19q status and
symptomatic or progressive low-grade glioma will be ran-
domly assigned to either radiotherapy or radiotherapy with
concurrent temozolomide followed by up to 12 cycles of
adjuvant temozolomide in the conventional 5-day schedule.
These two trials are poised to help understand the efficacy
and longer-term toxicity of therapy in these patients.
Alternative Dosing Schedules of Temozolomide at
Recurrence of Temozolomide-pretreated Gliomas
No standard of care has been defined for patients with
glioblastoma who relapse or progress on or after standard
temozolomide-based radiochemotherapy. A minority of pa-
tients will undergo second surgery; few patients are eligible
for re-irradiation. The most commonly used pharmacologic
agents administered at recurrence are nitrosoureas, the
vascular endothelial growth factor (VEGF) antibody, bevaci-
zumab, and a rechallenge with temozolomide.11-13 These
approaches are summarized and compared in Table 1. Pa-
tients with a treatment-free interval between the end of
adjuvant temozolomide and recurrence can be treated with
the standard 5 out of 28-days regimen. However, even for
these patients, and for all patients who experience treat-
KEY POINTS
● Concomitant and adjuvant temozolomide is the stan-
dard of care for newly diagnosed glioblastoma.
● Temozolomide alone or in combination with radio-
therapy ise being explored in ongoing trials in newly
diagnosed patients with low-grade and anaplastic
glioma.
● Rechallenge with alternative dosing schedules of
temozolomide is a valid treatment option in recur-
rent, temozolomide-pretreated glioblastoma.
● Nitrosoureas have become the gold standard compar-
ator arm for the evaluation of novel treatments in
recurrent glioblastoma.
Table 1. Activity of Temozolomide Rechallenge or Nitrosoureas in Patients with Recurrent Glioblastoma Pretreated with











Perry et al. 201016 (n  33) Temozolomide 28/28 3 15 27 Nd
Wick et al. 200913 (n  19) Temozolomide diverse 0 18 26 23
Progression after temozolomide
Perry et al. 201016 (n  28) Temozolomide 28/28 11 16 36 Nd
Wick et al. 200913 (n  28) Temozolomide diverse 17 21 29 29
Nitrosoureas
Van den Bent et al. 200927 (n  56) BCNU/temozolomide 10 10 24 31
Wick et al. 201024 (n  92) CCNU 4 7 19 30
Batchelor et al. 201026 (n  65) CCNU 9 12 25 44
Antiangiogenic agents
Kreisl et al. 200917 (n  48) Bevacizumab 35 16 29 31
Friedman et al. 200911 (n  85) Bevacizumab 28 43 39
Batchelor et al. 201026 (n  31) Cediranib 57 17 26 32
Wick et al. 201024 (n  174) Enzastaurin 3 6 11 28
Abbreviations: CR, complete response; PR, partial response; BCNU, carmustine; CCNU, lomustine.
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ment failure on, rather than after, standard adjuvant temo-
zolomide, various dose-intensified regimens of temozolomide
are being used, including: 1) 3 weeks on 1 week off, 2) 1 week
on 1 week off, or 3) continuous application, as exemplified in
the RESCUE concept.14-16
It has not been clarified which temozolomide rechallenge
regimen is most effective and tolerable in recurrent glioblas-
toma and whether the dose-intensified regimens overcome
chemoresistance mediated by the absence of MGMT pro-
moter methylation. In recurrent glioblastoma, the prognos-
tic value of the MGMT status has remained unclear.
The progression-free survival rates at 6 months were in
the range of 30% or more for bevacizumab in the phase II
trials that led to registration, and 20% for nitrosoureas in
clinical trials where these agents served as the control arm
(see below).11,17 The progression-free survival rate at 6
months was 25% in the RESCUE trial, which explored low
continuous dosing of temozolomide at 50 mg/m2 for patients
recurring during or after adjuvant temozolomide.16 The
DIRECTOR trial is a prospective, randomized, noncompara-
tive, open-label phase II trial that assesses the efficacy of the
1 week on 1 week off (120 mg/m2) and the 3 weeks on 1 week
off (80 mg/m2) regimens in patients with glioblastoma who
progress or relapse after standard first-line temozolomide
radiochemotherapy and at least two cycles of adjuvant
temozolomide. The primary endpoint is time-to-treatment
failure defined as progression, intolerability of study treat-
ment, or death as a result of any cause. Secondary endpoints
are progression-free survival, overall survival, response and
MGMT correlations.
The Re-emerging Role of Nitrosourea Compounds in
the Treatment of Progressive or Recurrent Gliomas
The use of older generation alkylating agents of the
nitrosourea family has experienced major changes in neuro-
oncology during the last 10 years. Approximately 30 years
ago, after radiotherapy had been defined as the best stan-
dard of care after surgery, the major interest was to define a
role for adjuvant chemotherapy in addition to radiotherapy
using various agents of that family, including carmustine,
CCNU, nimustin.18,19 Although none of these studies had
sufficient data quality—by modern standards—to demon-
strate the efficacy of adjuvant nitrosourea chemotherapy,
there was still a broad consensus that the chances of
long-term survival were increased by adjuvant chemother-
apy, albeit at the prize of significant hematologic toxicity.18
When temozolomide was approved for recurrent glioblas-
toma in Europe (although not in the United States), an
alkylating drug had, for the first time, found a well-defined
place in the treatment of recurrent glioblastoma.20 More-
over, temozolomide was also approved for recurrent anaplas-
tic gliomas both in Europe and in the United States.21 In
2005, when temozolomide was approved for newly diagnosed
glioblastoma, the general interest in chemotherapy for glio-
blastoma increased, and was associated with an increas-
ing use, or at least appreciation, of the role of nitrosourea
compounds for recurrent disease.3 In a world where glio-
blastoma patients were now eligible for any treatment at
recurrence, most had already been exposed to temozolomide
upfront.
Various uncontrolled studies using the above-mentioned
compounds demonstrated higher hematologic toxicity in
patients pretreated with temozolomide and progression-free
survival rates in the range of 20%.22 Nevertheless, outside
clinical trials, such agents became a standard of care,
especially in countries where the option to explore alterna-
tive dosing schedules of temozolomide outside clinical trials
is limited. Of note, only two trials have directly compared
nitrosourea-based regimens with temozolomide without
demonstrating differences in efficacy; the German NOA-04
trial identified similar efficacy, but less hematologic toxicity,
of temozolomide compared with the combination of PCV in
patients with newly diagnosed anaplastic gliomas, and the
British BR-12 trial reported similar efficacy and toxicity of
both regimens in chemotherapy-naive patients with recur-
rent grade 3/4 gliomas.6,23
Although the design of many trials performed in the
recurrent glioblastoma setting indicated that the efficacy of
nitrosoureas was considered to be rather low, various prom-
ising new agents experienced an impressive failure to dem-
onstrate superiority over nitrosoureas, mostly CCNU, as
demonstrated by the failed registration trials for enzastau-
rin, tradedersen, or cediranib, or the randomized phase II
trial for erlotinib performed by the EORTC.24-27 Notably, the
failure of the most potentially promising of these agents,
cediranib, has defined for the modern area of glioblastoma
trials that lomustine is an acceptable control arm for ran-
domized trials at recurrence. The unexpected outcome of the
cediranib trial has also facilitated the consensus that a
controlled trial randomizing lomustine and the VEGF anti-
body bevacizumab, and combinations thereof, as currently
planned by the EORTC, is worthwhile.
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